Amarin | AMRN - Current Liabilities


Amarin reported $194.46M in Current Liabilities for its fiscal quarter ending in December of 2025.





Current Liabilities Change Date
AbbVie USD 43.29B 3.9B Dec/2025
Alnylam Pharmaceuticals USD 1.47B 89.13M Dec/2025
Amarin USD 194.46M 12.23M Dec/2025
AstraZeneca USD 30.62B 3.44B Dec/2025
BioCryst Pharmaceuticals USD 196.07M 5.83M Dec/2025
DBV Technologies USD 49.48M 60K Sep/2025
Esperion Therapeutics USD 300.81M 58.22M Dec/2025
GlaxoSmithKline GBP 21.39B 57M Dec/2025
Halozyme Therapeutics USD 177.09M 660.14M Dec/2025
Heron Therapeutics USD 96.1M 6.39M Dec/2025
Ionis Pharmaceuticals USD 783M 120.46M Dec/2025
Nektar Therapeutics USD 53.54M 12.8M Dec/2025
Neurocrine Biosciences USD 743.4M 105.4M Dec/2025
Novartis USD 27.28B 4.72B Dec/2025